Clopidogrel Loading Dose Before PCI
For patients undergoing PCI, administer a 600 mg loading dose of clopidogrel regardless of whether they present with ACS or stable coronary disease. 1
Guideline-Based Recommendations
The 2011 ACC/AHA/SCAI PCI guidelines explicitly recommend a 600 mg loading dose of clopidogrel for both ACS and non-ACS patients undergoing PCI with stenting 1, 2. This represents a Class I recommendation with Level of Evidence B, meaning this is the standard of care supported by robust clinical data.
Key Dosing Points:
- Loading dose: 600 mg given before or at the time of PCI 1
- Maintenance: 75 mg daily starting after the loading dose 2
- Timing consideration: The loading dose should be given when an antiplatelet effect is needed within hours 3
Special Circumstance - Post-Fibrinolytic Therapy:
If the patient received fibrinolytic therapy:
- Give 300 mg within 24 hours of fibrinolysis
- Give 600 mg if more than 24 hours have elapsed since fibrinolysis 1
Evidence Supporting 600 mg Over 300 mg
The guideline recommendation for 600 mg is strongly supported by clinical trial data showing superior outcomes:
In STEMI patients undergoing primary PCI, the 600 mg dose compared to 300 mg resulted in 4:
- Lower 30-day mortality (1.9% vs 3.1%, p=0.03)
- Reduced reinfarction (1.3% vs 2.3%, p=0.02)
- Decreased stent thrombosis (1.7% vs 2.8%, p=0.04)
- No increase in bleeding complications
A separate STEMI study confirmed these findings, showing the 600 mg dose reduced the primary endpoint (death, MI, urgent revascularization, or stroke) to 1.4% versus 11.2% with 300 mg (p=0.013) 5.
Important Caveats
CYP2C19 Poor Metabolizers:
The FDA label carries a boxed warning that clopidogrel has reduced effectiveness in patients who are homozygous for nonfunctional CYP2C19 alleles 3. Consider using prasugrel or ticagrelor instead in these patients if genetic testing identifies poor metabolizer status 6.
Stable Angina Exception:
One study in stable angina patients showed no benefit of 600 mg over 300 mg 7. However, the guideline recommendation for 600 mg applies to all patients undergoing PCI (both ACS and non-ACS) 1, and the preponderance of evidence favors the higher dose for optimal platelet inhibition.
Drug Interactions:
Avoid concomitant use with strong CYP2C19 inhibitors (omeprazole, esomeprazole) as they significantly reduce clopidogrel's antiplatelet activity 3.
Duration of Therapy Post-PCI
After the loading dose, continue clopidogrel 75 mg daily for 1, 2:
- At least 12 months for any stent (BMS or DES) placed during ACS
- At least 12 months for DES in non-ACS patients (if not high bleeding risk)
- Minimum 1 month for BMS in non-ACS patients (ideally up to 12 months)